Trellis Bioscience Announces Positive Interim Phase 1 Results for TRL1068, a Novel Native Human Monoclonal Antibody Which Reduces Bacterial Biofilm Burden in Chronic Prosthetic Joint Infections

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 05/04/2023.
  • Additional Information
    • Alternate Title:
      TRELLIS-TRL1068-resul
    • Subject Terms:
    • Abstract:
      REDWOOD CITY, Calif., May 4, 2023 /PRNewswire/ -- Trellis Bioscience Inc, a clinical stage privately held biotechnology company focused on the discovery and development of native human monoclonal antibodies, today announced a clinical proof-of-concept milestone from a planned interim analysis of the company's Phase 1 trial of its lead antibody, TRL1068 (calpurbatug), in patients with prosthetic joint infections (PJI). TRL1068 has the potential to disrupt bacterial biofilm and thereby enable difficult-to-treat bacterial infections to be treated with standard antibiotics. [ABSTRACT FROM PUBLISHER]